Replicel (TSE:RP) has released an update.
RepliCel Life Sciences Inc. has proposed an asset sale to a company controlled by its CEO, aiming to secure an 8% royalty on future profits from its technologies in exchange for patents and other assets. The transaction seeks to provide a path forward for RepliCel amidst funding challenges and delayed commercialization. Shareholder approval is required, with a focus on avoiding bankruptcy and preserving shareholder value through eventual commercialization.
For further insights into TSE:RP stock, check out TipRanks’ Stock Analysis page.
